Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
FDA Approves Dupilumab as Add-On Maintenance Therapy For Adults With COPD
FDA approves dupilumab (Dupixent) as add-on therapy for adult COPD patients with eosinophilic phenotype, based on phase 3 trials BOREAS and NOTUS showing significant reduction in exacerbations, improved lung function, and quality of life. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 pathways, also approved for pediatric eosinophilic esophagitis and has multiple other indications.
Related Clinical Trials:
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab (Dupixent) as the first biologic treatment for uncontrolled COPD with an eosinophilic phenotype, based on phase 3 trials showing reduced exacerbations and improved lung function.
Related Clinical Trials:
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
FDA approves Dupixent for inadequately controlled COPD with eosinophilic phenotype, based on phase 3 studies showing significant reduction in exacerbations, improved lung function, and health-related quality of life.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
FDA approves Dupixent for COPD, making it the first biologic medicine for the condition in the U.S. This expansion is expected to boost sales, which reached almost $12 billion globally last year. Dupixent targets Type 2 inflammation in a subset of COPD patients, showing reduced exacerbations and improved lung function in trials. European regulators approved Dupixent for COPD in July, but U.S. approval required additional efficacy data. The approval comes as Regeneron faces market value loss due to a court case, increasing pressure on its pipeline.
FDA Approves Dupilumab (Dupixent) for Treatment of COPD
FDA approves dupilumab (Dupixent) for COPD, based on BOREAS and NOTUS trials, offering reduced exacerbations and improved lung function in patients with type 2 inflammation.
Dupixent approved in the US as the first-ever biologic medicine for patients
Dupixent approved by FDA as first biologic for COPD patients with eosinophilic phenotype, showing significant reduction in exacerbations and improvements in lung function and quality of life in phase 3 studies.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
FDA approves Dupixent for chronic obstructive pulmonary disease, based on late-stage trials showing reduced flare-ups and improved breathing in patients with uncontrolled symptoms driven by eosinophils.
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
The article discusses the importance of SSR (Server-Side Rendering) in modern web development for improving performance and SEO.
© Copyright 2024. All Rights Reserved by MedPath